Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies and is the third leading cause of tumor-related mortality worldwide. Despite advances in HCC treatment, diagnosis at the later stages, and the complex mechanisms relating to the cause and pathogenesis, results in less than 40% of HCC patients being eligible for potential therapy. Prolonged inflammation and resulting immunosuppression are major hallmarks of HCC; however, the mechanisms responsible for these processes have not been clearly elucidated. In this study, we identified SOCS-7, an inhibitor of cytokine signaling, as a novel regulator of immunosuppression in HCC. We found that SOCS-7 mediated E3 ubiquitin ligase activity on a signaling adaptor molecule, Shc1, in Huh-7 cells. Overexpression of SOCS-7 reduced the induction of immunosuppressive factors, TGF-β, Versican, and Arginase-1, and further reduced STAT3 activation. Furthermore, using an in vivo tumor model, we confirmed that SOCS-7 negatively regulates immunosuppression and inhibits tumor growth by targeting Shc1 degradation. Together, our study identified SOCS-7 as a possible therapeutic target to reverse immunosuppression in HCC.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
WHO. International Agency for Research on Cancer. Liver. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf (2018).
Golabi, P. et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 96, e5904 (2017).
Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64, S84–S101 (2016).
Balogh, J. et al. Hepatocellular carcinoma: a review. J. Hepatocell Carcinoma. 3, 41–53 (2016).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389, 2492–2502 (2017).
Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940–952 (2018).
Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature. 387, 917–921 (1997).
Ilangumaran, S., Ramanathan, S. & Rottapel, R. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol. 16, 351–365 (2004).
Hilton, D. J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA. 95, 114–119 (1998).
Huang, Y. et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132, 733–744 (2007).
Yang, R. et al. p53 induces miR199a-3p to suppress SOCS7 for STAT3 activation and renal fibrosis in UUO. Sci. Rep. 7, 43409 (2017).
Martens, N. et al. Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation. J. Biol. Chem. 280, 13817–13823 (2005).
Fu, B. et al. PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure. Cell Death Dis. 11, 803 (2020).
Sasi, W., Ye, L., Jiang, W. G., Sharma, A. K. & Mokbel, K. In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor. Biomed Res. Int. 2014, 648040 (2014).
Onnis, A. et al. The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II. Autophagy. 14, 2117–2138 (2018).
Wright, K. D. et al. The p52 isoform of SHC1 is a key driver of breast cancer initiation. Breast Cancer Res. 21, 74 (2019).
Ahn, R. et al. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun. 8, 14638 (2017).
Moreira, D. et al. STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers. Clin. Cancer Res. 24, 5948–5962 (2018).
Huang, P. et al. p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling. Exp. Cell Res. 383, 111550 (2019).
Guo, R. et al. MET IHC is a poor screen for MET amplification or MET Exon 14 mutations in lung adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J. Thorac. Oncol. 14, 1666–1671 (2019).
Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur. Urol. 76, 469–478 (2019).
Krebs, D. L. & Hilton, D. J. A new role for SOCS in insulin action. Suppressor of cytokine signaling. Sci. STKE. 2003, PE6 (2003).
Li, Y. et al. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat. Commun. 8, 347 (2017).
Piessevaux, J. et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J. Biol. Chem. 281, 32953–32966 (2006).
Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28, 29–35 (2001).
Niwa, Y. et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24, 6406–6417 (2005).
Weber-Nordt, R. M. et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88, 809–816 (1996).
Danial, N. N., Pernis, A. & Rothman, P. B. Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875–1877 (1995).
Lu, C. et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer 18, 130 (2019).
Chen, J. et al. Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-beta pathway. Gastroenterology 154, 195–210 (2018).
Tanaka, Y. et al. Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis 5, e277 (2016).
Zhangyuan, G. et al. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway. Oncogene 39, 1213–1230 (2020).
Kershaw, N. J., Murphy, J. M., Lucet, I. S., Nicola, N. A. & Babon, J. J. Regulation of Janus kinases by SOCS proteins. Biochem. Soc. Trans. 41, 1042–1047 (2013).
Matsuda, S., Saito, H. & Nishiyama, N. Basic fibroblast growth factor suppressed the enhancement of choline acetyltransferase activity induced by nerve growth factor. Neurosci. Lett. 114, 69–74 (1990).
Yu, S. et al. Autophagy in the “inflammation-carcinogenesis” pathway of liver and HCC immunotherapy. Cancer Lett. 411, 82–89 (2017).
The research is supported by National Natural Science Foundation of China (NSFC), No. 81772590, 81972233.
The authors declare no competing interests.
Ethics approval and consent to participate
All animal experimentation was approved by Institutional Animal Care and Use Committee of the Fudan University, Shanghai, China. All experiments were conducted according to guidelines approved by the Zhongshan Hospital affiliated with Fudan University.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Huang, P., Zhao, Z., Chen, Y. et al. The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma. Lab Invest 102, 613–620 (2022). https://doi.org/10.1038/s41374-022-00727-5